Atara Biotherapeutics Presents Preclinical Data On ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, At The 65th ASH Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced preclinical data on ATA3431, a next-generation allogeneic CD20/CD19-targeted CAR T-cell therapy, at the 65th ASH Annual Meeting. The data showed superior anti-tumor activity, survival, and functional persistence compared to autologous CAR-T benchmarks, with no observed treatment-related toxicities or alloreactivity. These findings support the advancement of ATA3431 into IND-enabling studies, with an IND submission planned for 2025. ATA3431 is built on Atara's EBV T-cell platform and does not require TCR or HLA gene editing. The preclinical results suggest potential for overcoming antigen escape, a major cause of treatment resistance or relapse in current CD19-targeted CAR-T treatments.
December 11, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atara Biotherapeutics' preclinical data for ATA3431 indicates a potential breakthrough in CAR T-cell therapy, which could position the company as a leader in the field and drive investor interest.
The positive preclinical data for ATA3431 suggests a competitive edge in the CAR T-cell therapy market, which is likely to generate investor optimism. The lack of observed toxicities and the potential to overcome antigen escape are particularly encouraging for future clinical trials and regulatory progress. This could lead to increased investor confidence and a positive short-term impact on ATRA's stock price.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100